Profile of human brain proteome in toxoplasma encephalitis co-infected with HIV. Clin Proteomics. 2014;11(1):39. ISSN 1542?6416. Dispon el em: http://www.ncbi.nlm.nih.gov/pubmed/25404878. 16. Rogeberg M et al. On-line solid phase extraction-liquid chromatography, with emphasis on modern bioanalysis and miniaturized systems. J Pharm Biomed Anal. 2014;87:120?. ISSN 1873-264X. Dispon el em: http://www. ncbi.nlm.nih.gov/pubmed/23746991. 17. DWIVEDI RC et al. Practical implementation of 2D HPLC scheme with accurate peptide retention prediction in both dimensions for highthroughput bottom-up proteomics. Anal Chem. 2008;80(18):7036?2. ISSN 1520?882. Dispon el em: http://www.ncbi.nlm.nih.gov/pubmed/18686972. 18. Wang Y et al. Reversed-phase chromatography with multiple fraction concatenation strategy for proteome profiling of human MCF10A cells. Proteomics. 2011;11(10):2019?6. ISSN 1615?861. Dispon el em: http://www.ncbi.nlm.nih.gov/pubmed/21500348. 19. May JC, MClean JA. Ion mobility-mass spectrometry: time-dispersive instrumentation. Anal PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/15501003 Chem. 2015;87(3):1422?6. ISSN 1520?882. Dispon el em: http://www.ncbi.nlm.nih.gov/pubmed/25526595. 20. Lanucara F et al. The power of ion mobility-mass spectrometry for structural characterization and the study of conformational dynamics. Nat Chem. 2014;6(4):281?4. ISSN 1755?349. Dispon el em: http://www.ncbi.nlm.nih. gov/pubmed/24651194. 21. Distler U et al. Drift time-specific collision energies enable deep-coverage data-independent acquisition proteomics. Nat Methods. 2014;11(2):167?0. ISSN 1548?105. Dispon el em: http://www.ncbi.nlm.nih.gov/pubmed/24336358.Submit your next manuscript to BioMed Central and we will help you at every step:?We accept pre-submission inquiries ?Our selector tool helps you to find the most relevant journal ?We provide round the clock customer support ?Convenient online submission ?Thorough peer review ?Inclusion in PubMed and all major indexing services ?Maximum visibility for your research Submit your manuscript at www.biomedcentral.com/submit
Hall et al. J Transl Med (2016) 14:129 DOI 10.1186/s12967-016-0875-zJournal of Translational MedicineOpen AccessRESEARCHNovel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatinJason C. Hall1*, Laura A. Marlow1, Adam C. Mathias4, Louis K. Dawson4, William F. Durham4, Kenneth A. Meshaw4, Robert J. Mullin4, Aidan J. Synnott4, Daniel L. Small4, Murli Krishna2, Daniel von Hoff5, Julia Sch er4, Steven N. Hart6, Fergus J. Couch6, Gerardo ColonOtero3 and Capivasertib John A. CoplandAbstract Background: Pancreatic acinar cell carcinoma (PACC) is a rare malignancy, accounting for <1 of all pancreatic neo plasms. Very few retrospective studies are available to help guide management. We previously reported the case of a patient with metastatic PACC who achieved prolonged survival following doxorubicin treatment. Personalized treat ment was based on molecular and in vitro data collected from primary cells developed from their liver metastasis. We now report the characterization of a patient derived tumor xenograft (PDTX) mouse model that originated from this patient's PACC liver metastasis. Methods: Fragments of biopsy tissue (5 mm3) from PACC liver metastasis were implanted into athymic nude mice. Tumors were grown and passaged from the host mice into new mice to be tested for therapeutic response. Immuno histochemical (IHC) biomarkers were used to confirm that the PDTX model represents.